Exelixis Inc. (NASDAQ:EXEL) shares fell 6.6% Monday after Merck announced its combination therapy outperformed Exelixis’ monotherapy Cabometyx in a late-stage kidney cancer trial. Merck’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results